Key Considerations for Developing a Direct-to-Patient (DtP) Strategy
This webinar we explore important considerations for developing a Direct-to-Patient strategy and the RTSM features needed to support its execution.
Download NowTopics discussed:
-
The impact of COVID-19 on clinical trials, including perspectives from patients, sites and sponsors
-
Whether or not DtP makes sense for you trial, and if so, what model?
-
The RTSM as a solution when implementing a robust DtP strategy
-
Key considerations for a DtP strategy, including an actionable checklist to discuss with your team
Senior Client Director
Neta Bendelac, 4G Clinical Client Director - Europe, has over 10 years of experience in Clinical Supply Chain Management. She headed the Clinical Supply Chain department at Teva Pharmaceuticals, where she established new and innovative approaches to managing IMPs in clinical trials, designing them with a highly acclaimed and unique patient perspective. Prior to Teva, Neta worked as an international Supply Chain consultant, providing simulations and optimization tools to clients worldwide. Neta holds a BS in Industrial Engineering and a Master of Business Administration (MBA) from Tel Aviv University, Israel. Neta is always focused on execution, finding joy in creative solutions to help patients around the world.